A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial-Reference-Cited by-同舟云学术

A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial

Published:2008-06-06 Issue:4 Volume:27 Page:359-364
ISSN:0929-5305
Container-title:Journal of Thrombosis and Thrombolysis
language:en
Short-container-title:J Thromb Thrombolysis

Author:

Morrow David A.,Brickman Chaim M.,Murphy Sabina A.,Baran Kenneth,Krakover Ricardo,Dauerman Harold,Kumar Sujatha,Slomowitz Natanya,Grip Laura,McCabe Carolyn H.,Salzman Andrew L.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Hematology

Link

http://link.springer.com/content/pdf/10.1007/s11239-008-0230-1.pdf

Reference15 articles.

1. Antman EM, Hand M, Armstrong PW et al (2007). 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation

2. Verma S, Fedak PW, Weisel RD et al (2002) Fundamentals of reperfusion injury for the clinical cardiologist. Circulation 105:2332–2336

3. Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121–1135

4. Thiemermann C, Bowes J, Myint FP et al (1997). Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci USA 94:679–683

5. Zingarelli B, Salzman AL, Szabo C (1998) Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res 83:85–94

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The PARP inhibitor rucaparib blocks SARS‐CoV‐2 virus binding to cells and the immune reaction in models of COVID‐19;British Journal of Pharmacology;2024-08-27

2. Probing intracellular determinants of PARP inhibitor selectivity and pharmacology with CeTEAM;2024-08-10

3. Cellular and molecular mechanisms of cell damage and cell death in ischemia–reperfusion injury in organ transplantation;Molecular Biology Reports;2024-03-29

4. Cardioprotective Effects of PARP Inhibitors: A Re-Analysis of a Meta-Analysis and a Real-Word Data Analysis Using the FAERS Database;Journal of Clinical Medicine;2024-02-21

5. Mechanisms of Cell Death in Ischemia-Reperfusion Injury in Organ Transplantation and Nitric Oxide as a Cytoprotectant;Gasotransmitters in Organ Transplantation;2024